Non-typhoidal salmonella (NTS) bacteremia is a significant cause of morbidity and mortality in HIV-infected individuals worldwide. Recent reports have noted increasing resistance of NTS isolates to fluoroquinolones, the recommended first-line therapy for NTS bacteremia. The outcomes and risk factors for NTS bacteremia in HIV-infected patients in an urban US setting were evaluated. From January 2002 to December 2006, 26 episodes of NTS bacteremia were identified in 16 patients. The risk factors for NTS bacteremia were low CD4 count, high viral load, and lack of antiretroviral therapy (ART). Recurrences appeared related to lack of immune reconstitution in patients not on ART. Unlike reports from Asia, no fluoroquinolone resistance was identified in any of the Salmonella strains isolated in this setting. Optimal treatment of NTS in the HIV-infected patient in the United States should include therapy with fluoroquinolones as well as attaining complete viral suppression and immune reconstitution with ART.
Arthur G., Nduba VN, Kariuki SM, Kimari J., Bhatt SM, Gilks CFTrends in bloodstream infections among human immunodeficiency virus-infected adults admitted to a hospital in Nairobi, Kenya, during the last decade. Clin Infect Dis. 2001;33(2): 248-256.
2.
Berkley JA, Lowe BS, Mwangi I., et al. Bacteremia among children admitted to a rural hospital in Kenya . N Engl J Med. 2005;352(1):39-47.
3.
Brent AJ, Oundo JO, Mwangi I., Ochola L., Lowe B., Berkley JASalmonella bacteremia in Kenyan children. Pediatr Infect Dis J. 2006;25(3):230-236.
4.
Bronzan RN, Taylor TE, Mwenechanya J., et al. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J Infect Dis. 2007;195(6): 895-904.
5.
Gordon MA, Banda HT, Gondwe M., et al. Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. AIDS. 2002;16(12): 1633-1641.
6.
Kiratisin P.Bacteraemia due to non-typhoidal Salmonella in Thailand: clinical and microbiological analysis. Trans R Soc Trop Med Hyg. 2008;102(4):384-388.
7.
Glaser JB, Morton-Kute L., Berger SR, et al. Recurrent Salmonella typhimurium bacteremia associated with the acquired immunodeficiency syndrome. Ann Intern Med. 1985;102(2):189-193.
Celum CL, Chaisson RE, Rutherford GW, Barnhart JL, Echenberg DFIncidence of salmonellosis in patients with AIDS. J Infect Dis. 1987;156(6):998-1002.
10.
Angulo FJ, Swerdlow DLBacterial enteric infections in persons infected with human immunodeficiency virus. Clin Infect Dis. 1995;21(suppl 1):S84-S93.
11.
Nelson MR, Shanson DC, Hawkins DA, Gazzard BGSalmonella, Campylobacter and Shigella in HIV-seropositive patients. AIDS. 1992;6(12):1495-1498.
12.
Casado JL, Valdezate S., Calderon C., et al. Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients. J Infect Dis. 1999; 179(6):1553-1556.
13.
Brown M., Eykyn SJNon-typhoidal Salmonella bacteraemia without gastroenteritis: a marker of underlying immunosuppression. Review Of cases at St. Thomas’ Hospital 1970-1999. J Infect. 2000;41(3):256-259.
Hung CC, Hung MN, Hsueh PR, et al. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance. Clin Infect Dis. 2007;45(5):e60-e67.
16.
Hung CC, Hsieh SM, Hsiao CF, Chen MY, Sheng WHRisk of recurrent non-typhoid Salmonella bacteraemia after early discontinuation of ciprofloxacin as secondary prophylaxis in AIDS patients in the era of highly active antiretroviral therapy. AIDS. 2001;15(5):645-647.
17.
Kaplan JE, Benson C., Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep.2009;58(RR-4):1-207.
18.
Chiu CH, Wu TL, Su LH, et al. The emergence in Taiwan of fluoroquinolone resistance in Salmonella enterica serotype Choleraesuis. N Engl J Med. 2002;346(6):413-419.
19.
Hakanen AJ, Kotilainen P., Pitkanen S., Huikko S., Siitonen A., Huovinen P.Reduction in fluoroquinolone susceptibility among non-typhoidal strains of Salmonella enterica isolated from Finnish patients. J Antimicrob Chemother. 2006;57(3):569-572.
20.
Skov MN, Andersen JS, Aabo S., et al. Antimicrobial drug resistance of Salmonella isolates from meat and humans, Denmark. Emerg Infect Dis. 2007 ;13(4):638-641.
21.
Akinyemi KO , Bamiro BS, Coker AOSalmonellosis in Lagos, Nigeria: incidence of Plasmodium falciparum-associated co-infection, patterns of antimicrobial resistance, and emergence of reduced susceptibility to fluoroquinolones. J Health Popul Nutr. 2007;25(3):351-358.
22.
Kariuki S., Revathi G., Kariuki N., Kiiru J., Mwituria J., Hart CACharacterisation of community acquired non-typhoidal Salmonella from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya . BMC Microbiol. 2006;6:101.
23.
Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2006. Vol. 18. Atlanta : US Department of Health and Human Services, Centers for Disease Control and Prevention; 2008: 31-34. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Accessed September 9, 2008.
24.
Clinical and Laboratory Standards Institute.Performance Standards for Antimicrobial Susceptibility Testing; Approved Standard Document M100-S16. Wayne, P. A. Clinical and Laboratory Standards Institute, 2006 .
